1,734 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Buy
Article Searches
GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology https://seekingalpha.com/article/4239823-glaxosmithkline-merck-kgaa-position-next-wave-immuno-oncology?source=feed_sector_healthcare Feb 11, 2019 - GSK collaborates with Merck KGaA on M7824, a TGF-beta.M7824 represents a class of agents considered to be the future of Immuno-Oncology.Late stage trials are needed to validate, M7824; if successful,
Incyte Down as FDA Extends Review Period of Jakafi for GVHD http://www.zacks.com/stock/news/353405/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd?cid=CS-ZC-FT-353405 Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark http://www.zacks.com/stock/news/353400/seattle-genetics-sgen-q4-loss-widens-revenues-top-mark?cid=CS-ZC-FT-353400 Feb 08, 2019 - Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs http://www.zacks.com/stock/news/353203/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs?cid=CS-ZC-FT-353203 Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
BioLineRx: With A Lot Of Cash In Hand And Undervalued https://seekingalpha.com/article/4238956-biolinerx-lot-cash-hand-undervalued?source=feed_tag_israel Feb 07, 2019 -
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $18. ... http://www.gurufocus.com/news/811679/merck--co-inc-mrk-chairman-president--ceo-kenneth-c-frazier-sold-181-million-of-shares Feb 06, 2019 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $18.1 million of Shares, Stocks: MRK, release date:Feb 06, 2019
Reflecting On Merck's 4Q Earnings The Two Things You Need To Know https://seekingalpha.com/article/4238378-reflecting-mercks-4q-earnings-two-things-need-know?source=feed_sector_healthcare Feb 06, 2019 -
Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer http://www.zacks.com/stock/news/352085/mercks-keytruda-clinches-chmp-nod-for-difficult-lung-cancer?cid=CS-ZC-FT-352085 Feb 05, 2019 - Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
What's Big Pharma Smoking Moving Into The Pot Field? https://seekingalpha.com/article/4237872-big-pharma-smoking-moving-pot-field?source=feed_sector_healthcare Feb 04, 2019 -
Why Merck (MRK) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/351811/why-merck-mrk-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-351811 Feb 04, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Pages: 123456789...174

<<<Page 4>